About the webinar:
Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative disease with limited treatment options and unmet medical needs. These high patient needs drive significant basic and drug discovery research, which requires relevant preclinical models.
In this webinar, Dr. Jessica Ramadhin introduces the SOD1 rat model, which expresses human SOD1 with the G93A mutation and develops various motor phenotypes. Senior Director of Neuroscience at Inotiv Boulder, Dr. Chris Butt, reviews new data generated in the model along with results from a 16-week longitudinal study in the SOD1 rat, including loss of motor coordination and progressive clinical degeneration, which correlate to the presence of the clinically relevant biomarker neurofilament light, a measure of neuronal damage. Watch this presentation for a discussion of relevant assays and endpoints for drug discovery research using this model.
View this webinar to:
- Discover how the G93A mutation is relevant to ALS and how the SOD1 rat was generated
- Understand how disease phenotype in the SOD1 rat can be monitored via key clinical observations, specific motor function assays, and biochemical characterization
- Uncover how variability in disease phenotype in the SOD1 rat is addressed in study planning
- Learn about the pros and cons of rats versus mice for neurodegenerative research
